Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo1IMvigor011 is the first global phase III study to read out pioneering a ctDNA- guided approach to post-surgery treatment in muscle-invasive bladder cancerData being presented as part of the Presidential Symposium at the ESMO Congress 2025 Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III IMvigor011 study evaluating Tecentriq® (atez ...